# A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

> **NCT07553988** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **R-Pharm International, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** RS-113, 160 mg
- **DRUG:** RS-113, 240 mg
- **DRUG:** RS-113, 320 mg
- **DRUG:** Abiraterone
- **DRUG:** Prednisolone
- **DRUG:** Androgen deprivation therapy (ADT)

## Key facts

- **NCT ID:** NCT07553988
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2026-05-14
- **Final completion:** 2027-05-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07553988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07553988, "A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07553988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*